The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.
This content originally appeared on our sister site, OncLive.
OncLive spoke with Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris Professor, chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, about future research efforts with CAR T-cell therapy in lymphoma.
CAR T-cell therapies are being evaluated in ongoing clinical trials for patients with lymphoma as well as other indications. Vose discussed how some studies are investigating different designs of CAR T-cell therapies, utilizing CAR T-cell therapy in various subtypes of lymphoma, and potentially incorporating the cellular therapy into earlier lines of treatment. These efforts may yield opportunities to decrease CAR T-cell therapy–related toxicities for patients, Vose explains.
Additionally, research efforts are evaluating whether combination regimens with CAR T-cell therapies and other agents, such as BTK inhibitors, are feasible for patients with lymphoma, Vose says. It may also be possible to utilize pre- and post-CAR T-cell therapy radiation to try to enhance efficacy, Vose continues. Additionally, evaluating different types of monoclonalantibodies, bispecific antibodies, or other new agents alone or in combination with CAR T-cell therapy could lend future treatment options for patients, Vose concludes.